Compare Cassava Sciences Inc (FLNA) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs LTC Properties Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while LTC Properties Inc trades at $43.29 (market cap $2.25B). The key difference: LTC Properties Inc is far larger — about 57.1× Cassava Sciences Inc's market cap, and LTC Properties Inc pays a 5.45% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and LTC Properties Inc for 89 Days on average.
| FLNA | LTC | |
|---|---|---|
Market Cap | $39.40M | $2.25B |
Volume | 759,018 | 1,238,557 |
Sector | Health | Real Estate |
52-Week High | $4.64 | $43.50 |
52-Week Low | $0.68 | $33.98 |
Typical Hold Time | 37 Days | 89 Days |
Enterprise Value | -$43.28M | $2.99B |
Dividend Yield | — | 5.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
LTC Properties trades at $41.81, down 1.48% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The REIT maintains strong profitability with 38.93% net margins and pays consistent monthly dividends of $0.19 per share. Recent acquisitions totaling $360 million accelerate the company's SHOP portfolio transformation, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with demographic tailwinds in senior housing but faces execution risks from aggressive expansion. The stock trades at reasonable valuations (P/E 14.93) with upside to analyst targets, though rising interest rates and integration challenges warrant caution for the growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
